

Driving patient health and independence

GRI 3-3



Goal

By 2030, we will expand our portfolio with innovative and pioneering devices to improve patient outcomes and independence.

Our work supports



SDG 3: Good Health and Well-Being

Using our products, patients can self-manage challenging health conditions, alternatively caregivers can help manage their conditions, outside of hospital settings.



SDG 8: Decent Work and Economic Growth

Our success depends on the growth and satisfaction of our people. We aim to provide a high-quality work environment where everyone receives competitive benefits.



SDG 9: Industry, Innovation and Infrastructure

We are committed to creating a reliable healthcare infrastructure for delivering necessary medications while consistently innovating to better serve our customers and their end users.



SDG 10: Reduced Inequalities

Our user-friendly autoinjectors reduce inequality related to medical accessibility for vulnerable populations like the elderly and chronically ill.

UNGC Principle 1

Businesses should support and respect the protection of internationally proclaimed human rights.

Target

Empower 8 million patients to live independently by 2030.

Progress

We reached 3.1M patients, a 40% increase compared to our 2022 base year.

We made strong progress towards this goal in 2023, partly driven by a rapid growth in demand for drugs that treat metabolic disorders, a trend that helped us exceed expectations by 14%.

Expand the reach of pioneering products to improve patient outcomes

Around the world, millions of people in both developed and developing nations still lack access to reliable, high-quality healthcare. This can not only impact their quality of life on a daily basis, but also shorten the lifespan of people with conditions like those listed below. Access to our products can help address these often-debilitating conditions.

- Atopic disorders
- Inflammatory bowel disease
- Management of weight and fertility issues
- Migraine
- Multiple sclerosis
- Postmenopausal osteoporosis
- Rheumatoid arthritis
- Type 2 diabetes

At SHL Medical, we have developed a versatile range of drug delivery systems that support the growing trend toward personalized medicine and less frequent injections. We leverage our experience to help pharmaceutical and biotech companies bring their combination products to market. This includes designing and developing the most suitable device solutions with drug characteristics and patient requirements in mind.

Innovation is key to our success, enabling us to develop device technology to support new therapeutic areas and markets. Our process considers user needs, accessibility, in-house capabilities, environmental footprint, and compliance to the relevant regulations and legislation.


Research and development

Our in-house Research and Development (R&D) capability provides us with a strategic advantage, allowing us to build an understanding of industry trends then develop technologies and approaches that reflect them. A significant example is the shift of patients' preference from intravenous to subcutaneous injections, utilizing high-volume, cartridge-based autoinjectors that can be safely administered from the comfort of their own homes.

In-house capabilities

SHL Medical is in a unique position among our peers, with our ability to fully manufacture devices in-house using modular product design. Insourcing critical manufacturing capabilities like tooling and final assembly gives us more flexibility and control over our supply chain. This in turn allows us to move products to local markets faster and more efficiently, helping us to better meet the demand for our autoinjectors.

End-to-end manufacturing of Molly®



Patient health: taking a patient-centered approach

Empowering a more independent standard for home care means putting patients' needs front and center. This is why we match our technical strengths with intensive care and testing, supporting our user-centric design. SHL Medical's global, in-house team of industrial designers, engineers, and usability experts work closely with our customers to ensure patient needs and user characteristics are accurately translated into device design and performance. This enables us to build data-informed devices that meet both our customers' needs and ensure safety and utility for caregivers and patients.



Molly® and Maggie®: a response to changing patient needs

The Molly® Connected Cap autoinjector is a good example of innovation and patient-centric design in action. The retrofitted connected cap technology can sense when the cap has been removed then emit a signal that can track patient usage in real time. This innovation helps patients and their caregivers tailor care based on injection frequency and timing. This more personalized approach heightens patient awareness, acceptance, and adherence.

In addition to an ergonomic design, Molly® also incorporates a push-on-skin activation that is accompanied by an audible click at the beginning and end of injection, as well as automatic needle cover lockout. These are all design elements designed to simplify use for the caregivers and patients.

Patient-preferred Needle Isolation Technology (NIT®)

Our product design can also remove barriers to treating conditions, especially when patients have concerns about the injection experience, such as a fear of needles. As a pre-installed needle housed within the cap of an autoinjector, the NIT technology eliminates the need for manual needle attachment, offering patients a more convenient device to use.

Product quality and safety

We build quality into every step of our processes, from product development to mass production, using a risk-based approach. All materials, components, and sub-assemblies are tested for compliance with international requirements using the latest, best-in-class inspection techniques and technologies. SHL Medical's Quality Management System (QMS) complies with FDA 21 CFR 820 and ISO 13485 standards to ensure a consistent and systemic approach that is monitored through internal audit procedures and is regularly audited by customers and notified bodies.

SHL Medical also complies with, as applicable and required, appropriate directives, regulations, standards, and guidance. In this way we can help ensure the safety and protection of end users and the environment while offering the best patient and customer experience.

